Company Overview

Actinium Pharmaceuticals, Inc. is a U.S.-based, clinical-stage biopharmaceutical company focused on the development of targeted radiotherapies for the treatment of cancer, primarily in hematologic malignancies. The company operates within the biotechnology and oncology therapeutics industries, with a strategic emphasis on alpha-emitting radiopharmaceuticals designed to selectively deliver cytotoxic radiation to cancer cells while minimizing damage to healthy tissue.

The company’s core value proposition is built around its proprietary alpha particle technology platform, which leverages targeted delivery mechanisms such as antibodies to improve therapeutic precision. Actinium was founded in 2000 and has evolved from early research-stage activities into a late-stage clinical development company, advancing multiple drug candidates through clinical trials and regulatory engagement, including interactions with the U.S. Food and Drug Administration.

Business Operations

Actinium’s operations are centered on the research, development, and clinical advancement of targeted radiotherapy product candidates. The company does not generate commercial product revenue and primarily funds operations through equity financing and strategic capital raises, as is typical for clinical-stage biotechnology firms. Its leading clinical programs include Iomab-B, a conditioning agent for bone marrow transplantation, and Actimab-A, a targeted therapy for acute myeloid leukemia.

The company conducts its activities primarily through internal research and development capabilities and collaborations with clinical research institutions. Manufacturing and certain development functions are supported through specialized third-party partners with expertise in radiopharmaceutical production and clinical trial execution. Actinium currently operates as a single reporting entity, and data regarding additional operating subsidiaries is inconclusive based on available public sources.

Strategic Position & Investments

Actinium’s strategy is focused on advancing its late-stage clinical assets toward potential regulatory approval while expanding the application of its alpha-emitter technology into additional oncology indications. Iomab-B represents the company’s most advanced asset and is positioned as a potential first-in-class therapy addressing unmet needs in bone marrow transplant conditioning for patients with relapsed or refractory leukemia.

The company has invested significantly in its technology platform to support pipeline expansion, including earlier-stage programs such as ATNM-500, which targets solid tumor indications. Actinium has not disclosed major completed acquisitions, and its growth strategy relies primarily on internal development, selective partnerships, and continued clinical validation of its platform. Information regarding equity investments in external portfolio companies is inconclusive based on available public sources.

Geographic Footprint

Actinium Pharmaceuticals, Inc. is headquartered in New York, United States, and its primary operations are based in the United States. Clinical trials sponsored by the company are conducted across multiple U.S. sites and, in some cases, include international research centers depending on trial design and regulatory approvals.

While the company does not maintain significant physical operations outside the United States, its clinical and regulatory activities give it a presence in North America and limited exposure to international markets through global clinical research collaborations. There is no verified evidence of large-scale commercial operations or manufacturing facilities outside the U.S. at this stage.

Leadership & Governance

Actinium is led by an executive team with experience in biotechnology, oncology drug development, and capital markets. The leadership emphasizes disciplined clinical execution, regulatory engagement, and the advancement of targeted radiotherapy as a differentiated therapeutic modality in oncology.

Key executives include:

• Sandesh Seth – Chief Executive Officer
• David Nicholson – Chairman of the Board

Publicly available sources confirm these leadership roles; however, detailed disclosures regarding additional senior executive appointments vary across filings, and data on other named executive officers is inconclusive based on available public sources.